Literature DB >> 22811874

How to overcome resistance to therapy?

Camilla Qvortrup, Sabine Tejpar, Per Pfeiffer.   

Abstract

Year:  2012        PMID： 22811874      PMCID： PMC3397646          DOI： 10.3978/j.issn.2078-6891.2012.015

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  6 in total

1.  Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.

Authors:  Halfdan Sorbye; Per Pfeiffer; Nina Cavalli-Björkman; Camilla Qvortrup; Mari H Holsen; Tore Wentzel-Larsen; Bengt Glimelius
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

2.  A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.

Authors:  Daniel Frank; Alcee Jumonville; Noelle K Loconte; William R Schelman; Daniel Mulkerin; Sam Lubner; Katie Richter; Natalie Winterle; Mary Beth Wims; Leah Dietrich; J Mitchell Winkler; Michael Volk; Kyungmann Kim; Kyle D Holen
Journal:  J Gastrointest Oncol       Date:  2012-06

3.  ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.

Authors:  Jeanette Dupont Jensen; Ann Knoop; Marianne Ewertz; Anne-Vibeke Laenkholm
Journal:  Breast Cancer Res Treat       Date:  2011-06-11       Impact factor: 4.872

4.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Authors:  Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-07-08       Impact factor: 41.316

5.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Authors:  Andrea Bertotti; Giorgia Migliardi; Francesco Galimi; Francesco Sassi; Davide Torti; Claudio Isella; Davide Corà; Federica Di Nicolantonio; Michela Buscarino; Consalvo Petti; Dario Ribero; Nadia Russolillo; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Luca Molinaro; Emanuele Valtorta; Andrea Sartore-Bianchi; Mauro Risio; Lorenzo Capussotti; Marcello Gambacorta; Salvatore Siena; Enzo Medico; Anna Sapino; Silvia Marsoni; Paolo M Comoglio; Alberto Bardelli; Livio Trusolino
Journal:  Cancer Discov       Date:  2011-09-02       Impact factor: 39.397

6.  Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.

Authors:  Hwang-Phill Kim; Young-Kwang Yoon; Jin-Won Kim; Sae-Won Han; Hyung-Seok Hur; Jinah Park; Ju-Hee Lee; Do-Youn Oh; Seock-Ah Im; Yung-Jue Bang; Tae-You Kim
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.